

DAFTAR PUSTAKA

- Alarcon, Friedman, Moulds, Straaton, dan Lisse, 2001, *Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort* cit. Fatoni, A.Z., 2007, Pengaruh Usia Onset, Rutinitas Minum Obat, Jenis Kelamin, Tingkat Penghasilan, Tingkat Pendidikan dan Durasi Penyakit terhadap Tingkat Aktivitas Penyakit pada Penderita SLE, Tugas Akhir, Fakultas Kedokteran Universitas Brawijaya, Malang.
- Alten, R., Maleitzke, T., 2013, Tocilizumab: a novel humanized antiinterleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic inflammatory rheumatic diseases, *Ann Med*, 45(4), 357-363.
- Anonim, 1999, American College of Rheumatology, *Guideline for Referral And Management of SLE in Adults*.
- Anonim, 2011, *Diagnosis dan Pengelolaan Lupus Erythematosus Sistemik*, Perhimpunan Reumatologi Indonesia.
- Anonim, 2013, Lupus Flares: Recognizing one, triggers, and prevention, <http://www.mollysfund.org/2013/07/lupus-flares-recognizing-one-triggers-and-prevention/#2>, diakses pada 03 Mei 2015 pukul 16.47 WIB.
- Anonim, 2013, Systemic Lupus Erythematosus (SLE), <http://rematik-autoimun.com/systemic-lupus-erythematosus-sle.html>, diakses pada 03 Mei 2015 pukul 10.39 WIB.
- Anonim, 2014, Proteinuria, www.kidney.niddk.nih.gov, diakses pada 20 April 2016 pukul 17.15 WIB.
- Anonim, 2016, Apa itu Lupus, http://www.academia.edu/9709898/Apa_itu_Lupus, diakses pada 21 April 2016 pukul 16.15
- Aringer, M., Burkhardt, H., Burmester, G.R., Fischer-Betz, R., Fleck, M., Graninger, W., ..., Dorner, T., 2012, Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report, *Lupus* 21(4), 386-401
- Bartels, C.M., Krause, R.S., Lakdawala, V.S., et al. Systemic Lupus Erythematosus (SLE). 2011. [cited 2011 Oct 6]. Available from : <http://emedicine.medscape.com/article/332244-overview>.

- Belmont, 2013, Treatment of Systemic Lupus Erythematosus, *Bulletin of the Hospital for Joint Diseases*, 71(3), 208-213.
- Corwin, E. J., 2001, *Patofisiologi*. Penerbit Buku Kedokteran EGC, Jakarta.
- Davis, J., 2008, Eculizumab, *Am. J. Health Syst. Pharm.*, 6(5), 1609–1615.
- D'Cruz DP, 2006, Systemic SLE erythematosus, dalam Dipiro, J. T., Talbert, R. L., Yee., G. C., Matzke, G. R., Wells, B. G., 7 Posey, M. L., *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed, McGrawHill, United State.
- Ding, H.J., Gordon C., 2013, New biologic therapy for systemic lupus erythematosus, *Curr Opin Pharmacol*, 13(3), 405-412.
- Dipiro, J. T., Talbert, R. L., Yee., G. C., Matzke, G. R., Wells, B. G., 7 Posey, M. L., 2008 *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed, McGrawHill, United State.
- Dubois, 2007, Systemic Lupus Erythematosus, 1342, Lippincot Williams and Wilkins, Philadelphia cit. Fatoni, A.Z., 2007, *Pengaruh Usia Onset, Rutinitas Minum Obat, Jenis Kelamin, Tingkat Penghasilan, Tingkat Pendidikan dan Durasi Penyakit terhadap Tingkat Aktivitas Penyakit pada Penderita SLE*, Tugas Akhir, Fakultas Kedokteran Universitas Brawijaya, Malang.
- Dworkin, R.H., O'Connor, A.B., Audette J., et al., 2010, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update, *Mayo Clinic Proc.*, 85(3, suppl):S3-S14
- Emadi, A., Brodsky, R.A., 2009, Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. *Am. J. Hematol*, 8(4), 699–701.
- Flanc, R.S., Roberts, M.A., Strippoli, G.F.M., Chadban, S.J., Kerr, P.G. and Atkins, R.C. ,2004, Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. *Am J Kidney Dis* 4(3), 197-208.
- Fatoni, A.Z., 2007, *Pengaruh Usia Onset, Rutinitas Minum Obat, Jenis Kelamin, Tingkat Penghasilan, Tingkat Pendidikan dan Durasi Penyakit terhadap Tingkat Aktivitas Penyakit pada Penderita SLE*, Tugas Akhir, Fakultas Kedokteran Universitas Brawijaya, Malang.

- Gordon, D.A., Klinkhoff, A.V., 2005, Second line agents, dalam Dipiro J. T., Talbert, R. L., Yee., G. C., Matzke, G. R., Wells, B. G., 7 Posey, M. L., *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed, McGrawHill, United State.
- Gunnarssoon, I., Jonsdottr, T., 2013, Rituximab treatment in lupus nephritis- where do we stand? *Lupus*, 22(4),381-390
- Hahn, B.H., 2001, Management of systemic SLE erythematosu, dalam Dipiro J. T., Talbert, R. L., Yee., G. C., Matzke, G. R., Wells, B. G., 7 Posey, M. L., *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed, McGrawHill, United State.
- Harrison, 1995, *Prinsip-prinsip Ilmu Penyakit Dalam*, diterjemahkan oleh Ahmad H. Asdie, Edisi 13, Vol 4, Penerbit Buku Kedokteran EGC, Jakarta.
- Hillmen, P., Young, N., Schubert, J., Brodsky, R., Socie, G., Muus, P., ..., Luzzatto L., 2006, The complement inhibitory eculizumab in paroxysmal nocturnal hemoglobinuria. *N. Engl. J. Med.*, 35(5),1233–1243.
- Isbagio, H., Albar Z, Kasjmir YI, ,2009, *SLE Eritematosus Sistemik*. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, et al, editor. *Ilmu Penyakit Dalam Jilid III*. Edisi kelima. Jakarta: Interna Publishing, 2565-2579.
- Karim, 2002, Mycophenolate mofetil for Sistemik Lupus Eritematosus Refractory to Other Immunosuppressive Agents, *Rheumatology*, 41,876-882
- Kumar, A., 2002, Indian Guidelines on the Management of SLE, *Journal Indian of Rheumatology Association*, (10), 80-96.
- Lacy, C.F., Amstrong L.L., Goldman P., Lance L.L., 2011, *Drug Information Handbook*. 20th edition lexi-comp,USA.
- Lin, H.W., Phan K, Lin S-J.,2006, Trends in off-label β blocker use: a secondary data analysis. *Clin Ther.* ,28(10),1736-1746.
- Mok, C.C., Ying, K.Y., Tang, S., Leung, C.Y., Lee, K.W., Ng, W.L. et al. 2004, Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. *Arthritis Rheum* 5(10)2559-2568.
- Moroni dkk.,2006, A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years, *Clin J Am Soc Nephrol* 1, 925–932.

- Phan, H., Leder, M., Fishley, M., Moeller, M., Nahata, M., 2010, Off label and unlicensed medication use and associated adverse drug events in a pediatric emergency department, *Pediatr EmergCare*, 26(6),424-430.
- Prince, Sylvia A., Wilson Lorraine, M., 1994, *Konsep Klinis Proses-proses Penyakit*, diterjemahkan oleh Peter Anugerah, Edisi keempat, Penerbit Buku Kedokteran EGC, Jakarta.
- Qureshi, Z.P., Liu, Y., Sartor, O., Chu, Y.H., Bennett, C.L., 2011, Enforcement actions involving Medicaid fraud and abuse, 1996-2009. *Arch Intern Med.*,171(8),785-787.
- Robak, E., Robak, T.,2009, Monoclonal antibodies in the treatment of systemic lupus erythematosus. *Curr. Drug Targets*, 2(10),26–37.
- Rosas, J., Touma Z., 2015, Proteinuria: Assessment andUtility in Lupus Nephritis, *J Rheumatol Muscular Syst.*,1(1).
- Schatz dkk., 2015, Adverse Drug Reactions, *Am J Health Syst Pharm*, 52,417-9.
- Shah, S.S., Hall, M., Goodman, D.M., 2007,et al. Off-label drug use in hospitalized children. *Arch Pediatr AdolescMed.*,161(3),282-290.
- Shirota, Y., Yarboro, C., Ilei, G.G., 2013, Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus, *Ann Rheum Dis*,72(1),118-28.
- Siregar, J. P. C., 2005, Farmasi Klinik Teori dan Penerapan, 240-241, Penerbit Buku Kedokteran EGC, Jakarta.
- Stafford, R.S., 2008, Regulating off-label drug use: rethinking the role of the FDA. *N Engl J Med.*,358(14),1427-1429.
- Wahl, D.G., Bounameaux, H., de Moerloose, P., Sarasin, F.P., 2000 Prophylactic antithrombotic therapy for patients with systemic SLE erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? dalam Dippiro J. T., Talbert, R. L., Yee., G. C., Matzke, G. R., Wells, B. G., 7 Posey, M. L., *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed, McGrawHill, United State.
- Wallace, 2007, *The Lupus Book*, diterjemahkan oleh Cahya Wiratama, PT Bentang Pustaka, Yogyakarta.
- Ward, M.M., Pyun, E., dan Studenski, S., 1995, Long-term Survival in Systemic Lupus Erythematosus Patient Characteristics Associated with Poorer Outcomes, *Arthritis&Rheumatism*, 38 (2), 274-283.

Yuliasih, J.S., dalam Sistemik Lupus Erytematosus (SLE), Tjokroprawiro, A., Poernomo, B.S, Djoko, S., dan Gatot, S., (Eds), 2007, Buku Ajar Ilmu Penyakit Dalam, 235-245, Airlangga University Press, Surabaya.